English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Sirnaomics Executive Director Dr. Xiaochang Dai to Deliver Keynote Speech at BIOHK2022
Dec 14, 2022 11:56 HKT
Polymer protection for vaccines and drugs
Dec 09, 2022 23:00 HKT
Led by Legend Capital, GS Biotech Completes Nearly CNY100 million Pre-A Round Financing
Dec 09, 2022 19:27 HKT
Novotech 荣获 2022 年亚太地区 CRO 临床试验最佳实践奖
Dec 07, 2022 06:00 HKT
Novotech 榮獲 2022 年亞太地區 CRO 臨床試驗最佳實踐獎
Dec 07, 2022 06:00 HKT
노보텍, 임상 시험 모범 사례로 2022년 아시아 태평양 CRO 상 수상
Dec 07, 2022 06:00 HKT
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
Dec 06, 2022 14:00 HKT
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Dec 06, 2022 11:00 HKT
PRENETICS公布回購計劃 為股東創造長期價值
Nov 30, 2022 22:50 HKT
Prenetics公布一项2,000万美元股份回购计划及获纳入MSCI全球微型股指数
Nov 30, 2022 22:45 HKT
Prenetics公布一項2,000萬美元股份回購計劃及獲納入MSCI全球微型股指數
Nov 30, 2022 22:44 HKT
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
Nov 30, 2022 22:43 HKT
針對現時主流變異株Omicron BA.4-5復必泰二價新冠疫苗已運抵港澳並即將開打
Nov 28, 2022 09:56 HKT
针对现时主流变异株Omicron BA.4-5复必泰二价新冠疫苗已运抵港澳并即将开打
Nov 28, 2022 09:55 HKT
Malaysian Genomics Sees Rise in Profit Margins for 1Q
Nov 23, 2022 17:30 HKT
CRO业务收入可观,模式动物新应用或成为百奥赛图业务增长新动能
Nov 17, 2022 13:02 HKT
CRO業務收入可觀,模式動物新應用或成為百奧賽圖業務增長新動能
Nov 17, 2022 13:01 HKT
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
Nov 16, 2022 23:00 HKT
《美國胃腸病學雜誌》發表君聖泰HTD1801 治療原發性硬化性膽管炎的臨床 II 期研究數據
Nov 16, 2022 10:01 HKT
《美国胃肠病学杂志》发表君圣泰HTD1801 治疗原发性硬化性胆管炎的临床 II 期研究数据
Nov 16, 2022 10:00 HKT
<< Previous  Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: